INOVIO PHARMACEUTICALS, INC. (INO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 3.5M 7M 10.5M Q3 '21: 291.7K Q4 '21: 839.1K Q1 '22: 199.1K Q2 '22: 784.4K Q3 '22: 9.2M Q4 '22: 124.7K Q1 '23: 114.9K Q2 '23: 226K Q3 '23: 388.4K Q4 '23: 102.7K Q1 '24: 0 Q2 '24: 100.8K Q3 '24: 0 Q4 '24: 117K Q1 '25: 65.3K Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '26: 0 Q2 '26: 0 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-120M -80M -40M 0 40M 80M 120M Q3 '21: -60M Q4 '21: -105.5M Q1 '22: -71.7M Q2 '22: -104.1M Q3 '22: -35.8M Q4 '22: -55.9M Q1 '23: -44M Q2 '23: -37M Q3 '23: -35.6M Q4 '23: -27.4M Q1 '24: -31.5M Q2 '24: -33.2M Q3 '24: -27.3M Q4 '24: -20.4M Q1 '25: -25.1M Q2 '25: -23.1M Q3 '25: -21.2M Q4 '25: -17.5M Q1 '26: -21.9M Q2 '26: -18.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-120M -80M -40M 0 40M 80M 120M Q3 '21: -60.2M Q4 '21: -106.9M Q1 '22: -79.1M Q2 '22: -108.5M Q3 '22: -37.8M Q4 '22: -54.5M Q1 '23: -40.6M Q2 '23: -35.5M Q3 '23: -33.9M Q4 '23: -25M Q1 '24: -30.5M Q2 '24: -32.2M Q3 '24: -25.2M Q4 '24: -19.4M Q1 '25: -19.7M Q2 '25: -23.5M Q3 '25: -45.5M Q4 '25: 3.8M Q1 '26: -19.7M Q2 '26: -6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '21: -46.5M Q4 '21: -37.9M Q1 '22: -61.9M Q2 '22: -50.5M Q3 '22: -67.5M Q4 '22: -36.3M Q1 '23: -36.7M Q2 '23: -32.3M Q3 '23: -29.1M Q4 '23: -26.3M Q1 '24: -28.8M Q2 '24: -28.2M Q3 '24: -27.4M Q4 '24: -19.7M Q1 '25: -26.9M Q2 '25: -20.8M Q3 '25: -21.6M Q4 '25: -19.4M Q1 '26: -21.6M Q2 '26: -18M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '21: -46.7M Q4 '21: -38.5M Q1 '22: -61.9M Q2 '22: -51.2M Q3 '22: -67.6M Q4 '22: -36.5M Q1 '23: -37M Q2 '23: -32.3M Q3 '23: -29.1M Q4 '23: -26.3M Q1 '24: -28.8M Q2 '24: -28.7M Q3 '24: -27.4M Q4 '24: -19.7M Q1 '25: -26.9M Q2 '25: -20.8M Q3 '25: -21.6M Q4 '25: -19.5M Q1 '26: -21.6M Q2 '26: -18M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 90M 180M 270M Q3 '19: 102.8M Q2 '20: 155.8M Q3 '20: 174.4M Q1 '21: 202.4M Q2 '21: 209.6M Q3 '21: 210.3M Q1 '22: 218.9M Q2 '22: 235.3M Q3 '22: 249.4M Q1 '23: 21.5M Q2 '23: 22M Q3 '23: 22.4M Q1 '24: 23.3M Q2 '24: 27.2M Q3 '24: 28.1M Q1 '25: 38.6M Q2 '25: 38.8M Q3 '25: 52.2M Q1 '26: 69.1M Q2 '26: 81.6M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-21.00 -14.00 -7.00 0.00 7.00 14.00 21.00 Q3 '21: -1.09 Q4 '21: -17.45 Q1 '22: -17.54 Q2 '22: -17.61 Q3 '22: -17.47 Q4 '22: -14.08 Q1 '23: -15.61 Q2 '23: -16.76 Q3 '23: -18.13 Q4 '23: -6.10 Q1 '24: -5.52 Q2 '24: -5.10 Q3 '24: -4.47 Q4 '24: -3.99 Q1 '25: -3.19 Q2 '25: -2.61 Q3 '25: -2.59 Q4 '25: -1.81 Q1 '26: -1.58 Q2 '26: -1.04 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.